CORRECTED-UPDATE 1-Wegovy maker Novo Nordisk appoints Jamey Millar head of its US business

Reuters02-04 01:35

CORRECTED-UPDATE 1-Wegovy maker <a href="https://laohu8.com/S/NVO">Novo Nordisk</a> appoints Jamey Millar head of its US business

Corrects day in paragraph 1 to Tuesday, not Wednesday, and dateline to Copenhagen

COPENHAGEN, Feb 3 (Reuters) - Danish drug maker Novo Nordisk NOVOb.CO said on Tuesday it had appointed Jamey Millar head of its U.S. business, and Hong Chow head of product and portfolio strategy.

The maker of weight-loss drug Wegovy said in a statement that Millar would take on the job on February 5, succeeding Dave Moore, and that Hong would start on February 15, replacing Ludovic Helfgott.

Before joining Novo Nordisk, Jamey worked for UnitedHealth Group, as CEO of Optum Specialty Holdings, while Hong joins Novo Nordisk from Merck Healthcare in Germany, it said.

(Reporting by Louise Rasmussen, editing by Anna Ringstrom)

((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608809343?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 01:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608809343","market":"us","top_or_hot":-1,"title":"CORRECTED-UPDATE 1-Wegovy maker Novo Nordisk appoints Jamey Millar head of its US business","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>CORRECTED-UPDATE 1-Wegovy maker <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> appoints Jamey Millar head of its US business</title></head><body><p>Corrects day in paragraph 1 to Tuesday, not Wednesday, and dateline to Copenhagen</p><p><span>COPENHAGEN, Feb 3 (Reuters)</span><span> - </span>Danish drug maker Novo Nordisk <span>NOVOb.CO</span> said on Tuesday it had appointed Jamey Millar head of its U.S. business, and Hong Chow head of product and portfolio strategy. </p><p>The maker of weight-loss drug Wegovy said in a statement that Millar would take on the job on February 5, succeeding Dave Moore, and that Hong would start on February 15, replacing Ludovic Helfgott. </p><p>Before joining Novo Nordisk, Jamey worked for UnitedHealth Group, as CEO of Optum Specialty Holdings, while Hong joins Novo Nordisk from Merck Healthcare in Germany, it said.</p><p> (Reporting by Louise Rasmussen, editing by Anna Ringstrom)</p><p> ((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CORRECTED-UPDATE 1-Wegovy maker Novo Nordisk appoints Jamey Millar head of its US business</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCORRECTED-UPDATE 1-Wegovy maker Novo Nordisk appoints Jamey Millar head of its US business\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-04 01:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>CORRECTED-UPDATE 1-Wegovy maker <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> appoints Jamey Millar head of its US business</title></head><body><p>Corrects day in paragraph 1 to Tuesday, not Wednesday, and dateline to Copenhagen</p><p><span>COPENHAGEN, Feb 3 (Reuters)</span><span> - </span>Danish drug maker Novo Nordisk <span>NOVOb.CO</span> said on Tuesday it had appointed Jamey Millar head of its U.S. business, and Hong Chow head of product and portfolio strategy. </p><p>The maker of weight-loss drug Wegovy said in a statement that Millar would take on the job on February 5, succeeding Dave Moore, and that Hong would start on February 15, replacing Ludovic Helfgott. </p><p>Before joining Novo Nordisk, Jamey worked for UnitedHealth Group, as CEO of Optum Specialty Holdings, while Hong joins Novo Nordisk from Merck Healthcare in Germany, it said.</p><p> (Reporting by Louise Rasmussen, editing by Anna Ringstrom)</p><p> ((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1732800096.USD","symbol_name":"摩根大通环球收益基金A (irc)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nL8N3YZ28W:1","article_id":"2608809343","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608809343","pubTimestamp":1770140107,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CORRECTED-UPDATE 1-Wegovy maker Novo Nordisk appoints Jamey Millar head of its US businessCorrects day in paragraph 1 to Tuesday, not Wednesday, and dateline to CopenhagenCOPENHAGEN, Feb 3 (Reuters) -","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1732800096.USD":"摩根大通环球收益基金A (irc)","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","UNH":"联合健康","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","UNHG":"2倍做多UNH ETF-Leverage Shares","BK4588":"碎股","BK4532":"文艺复兴科技持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","IE00B4JS1V06.HKD":"JANUS HENDERSON BALANCED \"A2\" (HKD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","UNHW":"Roundhill UNH WeeklyPay ETF","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD"},"translate_title":"Wegovy制造商诺和诺德任命Jamey Millar为其美国业务主管","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UNH":0.9,"UNHG":0.6,"UNHW":0.6},"content_text":"CORRECTED-UPDATE 1-Wegovy maker Novo Nordisk appoints Jamey Millar head of its US businessCorrects day in paragraph 1 to Tuesday, not Wednesday, and dateline to CopenhagenCOPENHAGEN, Feb 3 (Reuters) - Danish drug maker Novo Nordisk NOVOb.CO said on Tuesday it had appointed Jamey Millar head of its U.S. business, and Hong Chow head of product and portfolio strategy. The maker of weight-loss drug Wegovy said in a statement that Millar would take on the job on February 5, succeeding Dave Moore, and that Hong would start on February 15, replacing Ludovic Helfgott. Before joining Novo Nordisk, Jamey worked for UnitedHealth Group, as CEO of Optum Specialty Holdings, while Hong joins Novo Nordisk from Merck Healthcare in Germany, it said. (Reporting by Louise Rasmussen, editing by Anna Ringstrom) ((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608809343","isCrawlerRequest":true}